Last updated: 11/04/2018 10:25:43

Effects of two doses of a common cold treatment on alertness

GSK study ID
RH01361
See study documents
Clinicaltrials.gov ID
NCT01686646
See results summary
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Effects of two doses of a common cold treatment on cognitive function
Trial description: This study will investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering the common cold, when taking a novel paracetamol and caffeine combination verses paracetamol alone.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Change from baseline in number of accurate responses to Rapid Visual Information Processing (RVIP) Cognitive test

Timeframe: Baseline to 60 minutes post treatment administration

Secondary outcomes:

Change from baseline in number of accurate responses to RVIP Cognitive test

Timeframe: Baseline to 120 minutes post treatment administration

Change from baseline in mean time of accurate responses to RVIP Cognitive Task

Timeframe: Baseline, 60 minutes and upto 120 minutes post treatment administration

Change from baseline in number of inaccurate and missed responses to RVIP Cognitive Task

Timeframe: Baseline, 60 minutes and up to 120 minutes post treatment administration

Change from baseline in number of accurate responses to Sustained Attention Tasks (SAT) Cognitive test

Timeframe: Baseline, 60 minutes and up to 120 minutes post treatment administration

Change from baseline in mean time of accurate responses to SAT Cognitive Task

Timeframe: Baseline, 30 minutes and up to 60 minutes post treatment administration

Change from baseline in number of incorrect and missed responses to SAT Cognitive test

Timeframe: Baseline, 60 minutes and up to 120 minutes post treatment administration

Change from baseline in number of valid responses to Divided Attention Task (DAT) Cognitive test

Timeframe: Baseline, 60 minutes and up to 120 minutes post treatment administration

Change from baseline in mean time of accurate responses to DAT Cognitive test

Timeframe: Baseline, 60 minutes and up to 120 minutes post treatment administration

Change from baseline in number of incorrect and missed responses to DAT Cognitive test

Timeframe: Baseline, 60 minutes and up to 120 minutes post treatment administration

Interventions:
Drug: paracetamol + caffeine
Drug: paracetamol
Enrollment:
240
Observational study model:
Not applicable
Primary completion date:
2012-30-11
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Common cold
Product
caffeine, paracetamol
Collaborators
Not applicable
Study date(s)
November 2011 to November 2012
Type
Interventional
Phase
3

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
  • Participants with symptoms of cold < 96 hours, rating of at least '2' on malaise at least 4 other symptoms of cold.
  • No history of clinically significant perennial rhinitis, no recent antibiotic, antihistamine or cold treatment, no caffeine in the previous 12 hours, no psychoactive medication in the 14 days prior to screening, no pregnancy, breastfeeding or participation in this trial, or another trial in the 30 days prior to screening.
Inclusion and exclusion criteria
Inclusion criteria:
  • Participants with symptoms of cold < 96 hours, rating of at least '2' on malaise at least 4 other symptoms of cold.
  • No history of clinically significant perennial rhinitis, no recent antibiotic, antihistamine or cold treatment, no caffeine in the previous 12 hours, no psychoactive medication in the 14 days prior to screening, no pregnancy, breastfeeding or participation in this trial, or another trial in the 30 days prior to screening.

Trial location(s)

Location
Status
Contact us
Contact us
Location
Common Cold Centre
Cardiff, Wales, United Kingdom, Not Available
Status
Study Complete
Contact us

Study documents

Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2012-30-11
Actual study completion date
2012-30-11

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website